Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
News|Podcasts|August 8, 2023
CDPHP's Kathy Leyden on Food Insecurity Programs
Author(s)Pearl Steinzor
On this episode of Managed Care Cast, Kathy Leyden, vice president of community engagement at Capital District Physicians' Health Plan (CDPHP), discusses key initiatives and areas of focus to address hunger and food insecurity issues across Upstate New York.
Advertisement
During her 10 years at Capital District Physicians' Health Plan (CDPHP), Kathy Leyden, vice president of community engagement at CDPHP, led efforts to develop a portfolio of social determinant of health interventions and has leveraged a wide variety of community engagement activities to enhance positive brand visibility and collaborate with external partners to build healthier and more equitable communities throughout the CDPHP service area.
Advertisement
Related to this article
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5